Yarpa and LBO France sell Izo to Vaxxinova
Yarpa Investimenti and LBO France have sold Izo, an Italy-based pharmaceutical company, to German trade buyer Vaxxinova.
Under the ownership of Yarpa and LBO, the business expanded its international distribution network. It will seek to continue with this strategy under its new owner.
The sale comes shortly after Yarpa exited Lag, an italian producer of pre-baked bread, to trade buyer Vandemoortele.
Previous funding
Yarpa and LBO wholly acquired Izo for a reported €15.2m from Gruppo Morini di Faenza in 2012.
Company
Headquartered in Brescia and founded in 1969, Izo is a producer of animal vaccines.
People
Claudio Garavaglia is CEO of Yarpa.
Advisers
Equity – NCTM Studio Legale, Matteo Trapani, Lucia Corradi (Legal).
More on Exits
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Ares Management handed keys to two-thirds of UK sponsor’s portfolio
Lender provided GBP 500m for three of the GP's deals between 2016 and 2019, Debtwire reported
Actera Group explores strategic options for Celebi Ground Handling
Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal
Main Capital’s Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater